Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

US11667722B2 · kind B2 · utility

Assignee

• Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft · DE

Inventors

• Martin Lipp · Berlin, DE
• Felix Oden · Berlin, DE
• Uta Höpken · Berlin, DE
• Gerd Muller · Jena, DE
• Oliver Daumke · Berlin, DE
• Stephen Marino · Berlin, DE
• Daniel Olal · Berlin, DE

Key dates

• Filing date: Jul 8, 2020
• Grant date: Jun 6, 2023
• Expiry date: Jun 12, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A composition comprising a cell or a population thereof, wherein the cell comprises a polynucleotide encoding an antibody or a fragment thereof that binds CD269 (BCMA), wherein the binding to CD269 (BCMA) disrupts the interaction between CD269 and its native ligands (BAFF and APRIL). Also disclosed is treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.